ClinicalTrials.Veeva

Menu
E

Evolution Research Group | Clinical Pharmacology of Miami

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CTP-543
Isavuconazole
Risankizumab
Disodium Salt
Glucose
BMS-986177
Levoketoconazole
SSP-004184
DA-1241
Fruquintinib

Parent organization

This site is a part of Evolution Research Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 128 total trials

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid o...

Enrolling
Healthy
Drug: Citrate-Free Mirikizumab

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide (BLV)

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability,...

Invitation-only
Healthy
Drug: VG-3927
Drug: Placebo

This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy...

Enrolling
Healthy Participants
Drug: Placebo
Drug: PMN310

The purpose of this study is to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participa...

Enrolling
Hepatic Impairment
Non-alcoholic Steatohepatitis
Drug: Efinopegdutide

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in partic...

Enrolling
Healthy
Hepatic Insufficiency
Drug: LY3502970

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in p...

Enrolling
Hepatic Impairment (HI)
Drug: Nemtabrutinib

PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesi...

Enrolling
Bunion
Drug: Ropivacaine

This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of B...

Enrolling
Obesity
Non-alcoholic Fatty Liver Disease
Drug: BI 3006337
Drug: Placebo matching BI 3006337

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, b...

Enrolling
Obesity
Drug: Placebo to DA-1726
Drug: DA-1726

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling
Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measur...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subj...

Enrolling
NON-ALCOHOLIC STEATOHEPATITIS
Drug: Sitagliptin
Drug: DA-1241 Placebo

Trial sponsors

Lilly logo
Shire logo
AbbVie logo
Astellas logo
Bayer logo
Bristol-Myers Squibb (BMS) logo
Concert Pharmaceuticals logo
Amgen logo
Gilead Sciences logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems